Showing 2531-2540 of 8826 results for "".
Dermwire TV: 2025 in Review
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-2025-in-review/54093/Dermwire TV takes a look back at the most popular stories from the Practical Dermatology news and multimedia ecosystem.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaThe Evolving Needs of the Modern Patient
https://practicaldermatology.com/series/c-suite-chats/the-evolving-needs-of-the-modern-patient/39900/Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs.DWTV Extra: Psoriasis Advocacy
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-psoriasis-advocacy/39890/International Federation of Psoriasis Associations (IFPA) executive director Frida Dunger discusses her organization's efforts to raise awareness, including a recent event involving the United Nations as well as World Psoriasis Day on October 29.DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.Increased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.Dermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldWhat’s New in Rosacea Treatments?
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39737/James Q. Del Rosso, DO, FAOCD, reviews the latest therapeutic innovations and evidence in rosacea management. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://reachmd.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to priv